|
Clerk of the House of Representatives Legislative Resource Center 135 Cannon Building Washington, DC 20515 http://lobbyingdisclosure.house.gov |
Secretary of the Senate Office of Public Records 232 Hart Building Washington, DC 20510 http://www.senate.gov/lobby |
LOBBYING REGISTRATION
Lobbying Disclosure Act of 1995 (Section 4)
| 1. Effective Date of Registration | 07/15/2014 |
||||
| 2. House Identification | 42677 |
Senate Identification | 401103351 |
||
REGISTRANT Organization/Lobbying Firm Self Employed Individual
| 3. Registrant | Organization | CapitalHill Advisory |
||||
| Address | 1717 Pennsylvania Ave NW Suite 1025 |
Address2 | |
| City | Washington DC |
State | DC |
Zip | 20006 |
Country | USA |
4. Principal place of business (if different than line 3)
| City | Sydney |
State | |
Zip | 2000 |
Country | AUS |
| 5. Contact name and telephone number | International Number |
| Contact | Ms. Cathy Duncan |
Telephone | 0292230311 |
cd@capitalhilladvisory.com.au |
CLIENT A Lobbying Firm is required to file a separate registration for each client. Organizations employing in-house lobbyists should check the box labeled “Self” and proceed to line 10. Self
| 7. Client name | Novartis Pharmaceuticals Pty Ltd ( Australia) |
| Address | 54 Waterloo Rd |
| City | North Ryde |
State | |
Zip | 2113 |
Country | AUS |
| City | |
State | |
Zip | |
Country | |
LOBBYISTS
10. Name of each individual who has acted or is expected to act as a lobbyist for the client identified on line 7. If any person listed in this section has served as a “covered executive branch official” or “covered legislative branch official” within twenty years of first acting as a lobbyist for the client, state the executive and/or legislative position(s) in which the person served.
| Name | Covered Official Position (if applicable) | ||
First |
Last |
Suffix |
|
| Nick | Campbell | Mr | |
| | | | |
| | | | |
| | | | |
| | | | |
LOBBYING ISSUES
11. General lobbying issue areas (Select all applicable codes).
ECN |
GOV |
PHA |
TAX |
|
|
|
|
|
12. Specific lobbying issues (current and anticipated)
Privileged & Confidential The Australian Government's policy of initiating court proceedings to recovered damages from innovative pharmaceutical companies in cases where patents covering pharmaceutical benefits scheme (PBS)- listed medicines have been found invalid following an initial grant of an interlocutory injunction which delayed the launch of generic products
AFFILIATED ORGANIZATIONS
13. Is there an entity other than the client that contributes more than $5,000 to the lobbying activities of the registrant in a quarterly period and either participates in and/or in whole or in major part supervises or controls the registrant’s lobbying activities?
| No --> Go to line 14. | Yes --> Complete the rest of this section for each entity matching the criteria above, then proceed to line 14. |
| Internet Address: | |
| Name | Address | Principal Place of Business | ||||||||
| Street | ||||||||||
|
||||||||||
|
|
|
||||||||
|
|
|||||||||
|
|
|
||||||||
|
|
|||||||||
|
|
|
||||||||
|
|
FOREIGN ENTITIES
14. Is there any foreign entity
a) holds at least 20% equitable ownership in the client or any organization identified on line 13; or
b) directly or indirectly, in whole or in major part, plans, supervises, controls, directs, finances or subsidizes activities of the client or any organization identified on line 13; or
c) is an affiliate of the client or any organization identified on line 13 and has a direct interest in the outcome of the lobbying activity?
| No --> Sign and date the registration. | Yes --> Complete the rest of this section for each entity matching the criteria above, then sign the registration. |
| Address | Ownership | |||||
| Name | Street | Principal place of business | Amount of contribution | |||
|
(city and state or country) | for lobbying activities | ||||
CH 4002 Basel |
|
|||||||||||
Novartis Int. |
|
|
0.00 |
100 |
% | |||||||
|
|
|||||||||||
|
|
|
|
|
% |
| Signature | Digitally Signed By: Cathy Duncan |
Date | 09/01/2014 |